^
    Apply
    SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma (NCT04923126)
    Phase 1/2
    St. Jude Children's Research Hospital
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    06/21/2021
    Primary completion :
    06/01/2031
    Completion :
    06/01/2031
    BRAF • NF1 • PTPN11 • MYBL1
    |
    BRAF mutation
    |
    Gomekli (mirdametinib)
    Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer (NCT02152995)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    08/14/2014
    Primary completion :
    08/25/2021
    Completion :
    01/25/2026
    HER-2 • KRAS • BRAF • NRAS • HRAS • EGF
    |
    KRAS mutation • NRAS mutation • BRAF V600 • BRAF wild-type • RAS wild-type • HRAS mutation • KRAS G12 • NRAS Q61 • KRAS G13 • NRAS G12 • NRAS G13 • KRAS Q61
    |
    Mekinist (trametinib) • omipalisib (GSK2126458)
    Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) (NCT05564403)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    02/09/2024
    Primary completion :
    01/21/2026
    Completion :
    01/21/2026
    MAPK1
    |
    BRAF V600E • BRAF V600
    |
    Mektovi (binimetinib) • oxaliplatin • leucovorin calcium • fluorouracil topical
    Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer (NCI-2021-11793) (NCT05111561)
    Phase 1
    National Cancer Institute (NCI)
    Suspended
    Last update posted :
    02/21/2025
    Initiation :
    08/02/2022
    Primary completion :
    03/14/2025
    Completion :
    03/14/2025
    HER-2 • KRAS • BRAF • ER • PGR • NRAS • HRAS • NF1
    |
    BRAF mutation • HER-2 amplification • HRAS mutation • BRAF fusion
    |
    Mektovi (binimetinib) • ZEN-3694
    Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial (NCT05554367)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    12/13/2023
    Primary completion :
    08/26/2026
    Completion :
    08/26/2026
    KRAS • BRAF • NRAS • HRAS • RAS
    |
    BRAF V600E • KRAS mutation • KRAS G12C • HRAS mutation • KRAS G12
    |
    Ibrance (palbociclib) • Mektovi (binimetinib)
    PASS of Paediatric Patients Initiating Selumetinib (NCT05388370)
    Phase N/A
    AstraZeneca
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    05/23/2022
    Primary completion :
    05/23/2028
    Completion :
    05/23/2028
    NF1
    |
    Koselugo (selumetinib)
    Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial (NCT05554328)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    04/25/2023
    Primary completion :
    10/01/2028
    Completion :
    10/01/2028
    KRAS • BRAF • NRAS • HRAS • MAP2K1 • NF1 • MAP2K2
    |
    KRAS mutation • BRAF mutation • NRAS mutation • RAS mutation • HRAS mutation
    |
    Lynparza (olaparib) • Koselugo (selumetinib)
    Observational Study to Evaluate the Effect and Safety of Selumetinib in Pediatric Patients With NF1-PNs (PEDIA) (NCT06175637)
    Phase N/A
    AstraZeneca
    Recruiting
    Last update posted :
    02/18/2025
    Initiation :
    12/20/2023
    Primary completion :
    11/30/2027
    Completion :
    11/30/2027
    NF1
    |
    Koselugo (selumetinib)
    Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %. (IMMUNOMEK) (NCT05937906)
    Phase 1/2
    Centre Georges Francois Leclerc
    Recruiting
    Last update posted :
    02/18/2025
    Initiation :
    07/30/2024
    Primary completion :
    05/25/2028
    Completion :
    05/25/2028
    PD-L1
    |
    Keytruda (pembrolizumab) • carboplatin • Gomekli (mirdametinib)
    Vemurafenib and Cobimetinib in Treating Patients with BRAF V600E Mutation Positive Craniopharyngioma (NCT03224767)
    Phase 2
    Alliance for Clinical Trials in Oncology
    Active, not recruiting
    Last update posted :
    02/18/2025
    Initiation :
    01/05/2018
    Primary completion :
    10/01/2026
    Completion :
    08/01/2028
    CYP1A2
    |
    BRAF V600E • BRAF V600
    |
    Zelboraf (vemurafenib) • Cotellic (cobimetinib)
    A Study of Avutometinib and Defactinib in People With Thyroid Cancer (NCT06007924)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    08/16/2023
    Primary completion :
    08/16/2027
    Completion :
    08/16/2027
    BRAF • ALK • RET • NF1 • NTRK
    |
    BRAF V600E • ALK rearrangement • BRAF V600K • RAS mutation • RET mutation • RET rearrangement
    |
    avutometinib (VS-6766) • defactinib (VS-6063)
    A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma (NCT03871257)
    Phase 3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    01/15/2020
    Primary completion :
    12/31/2030
    Completion :
    12/31/2030
    NF1
    |
    carboplatin • Koselugo (selumetinib) • vincristine
    Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction (NCT02070549)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    02/13/2025
    Initiation :
    03/10/2014
    Primary completion :
    12/18/2024
    Completion :
    12/18/2024
    BRAF
    |
    BRAF V600E • BRAF V600
    |
    Mekinist (trametinib) • omipalisib (GSK2126458)
    A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma (NCT04166409)
    Phase 3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    01/31/2020
    Primary completion :
    12/31/2030
    Completion :
    12/31/2030
    BRAF • NF1
    |
    BRAF V600E • BRAF V600
    |
    carboplatin • Koselugo (selumetinib) • vincristine
    Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial) (NCT05554354)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/12/2025
    Initiation :
    09/13/2024
    Primary completion :
    11/01/2026
    Completion :
    11/01/2026
    HER-2 • ER • PGR • NF1
    |
    HER-2 negative
    |
    Mektovi (binimetinib) • fulvestrant
    Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer (NCT02188264)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    02/11/2025
    Initiation :
    08/29/2014
    Primary completion :
    01/31/2017
    Completion :
    04/26/2019
    BRAF • RAF1 • MAPK1
    |
    BRAF mutation • RAS mutation
    |
    Koselugo (selumetinib) • cyclosporin A microemulsion
    AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors (SPRINT) (NCT01362803)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/11/2025
    Initiation :
    09/21/2011
    Primary completion :
    01/01/2027
    Completion :
    01/01/2032
    NF1
    |
    Koselugo (selumetinib)
    Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors (NCT02079740)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/11/2025
    Initiation :
    03/26/2014
    Primary completion :
    12/01/2022
    Completion :
    03/07/2025
    KRAS • NRAS • BCL2L2
    |
    KRAS mutation • NRAS mutation
    |
    Mekinist (trametinib) • navitoclax (ABT 263) • omipalisib (GSK2126458)
    Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPK (MIRV) (NCT06666348)
    Phase 1/2
    C17 Council
    Not yet recruiting
    Last update posted :
    02/11/2025
    Initiation :
    04/01/2025
    Primary completion :
    04/01/2030
    Completion :
    04/01/2035
    BRAF
    |
    Gomekli (mirdametinib) • vinblastine
    A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib (DURAFAK) (NCT05512208)
    Phase 2
    University of Oklahoma
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    02/06/2023
    Primary completion :
    12/01/2027
    Completion :
    12/01/2029
    BRAF • NF1 • RAS
    |
    BRAF mutation • RAS mutation
    |
    avutometinib (VS-6766) • defactinib (VS-6063)
    Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation (NCI-2018-01218) (NCT03065387)
    Phase 1
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    10/31/2017
    Primary completion :
    10/01/2025
    Completion :
    10/01/2025
    HER-2 • KRAS • ERBB3 • ERBB4
    |
    KRAS mutation • EGFR mutation • HER-2 amplification • EGFR amplification
    |
    Mekinist (trametinib) • Ibrance (palbociclib) • everolimus • Nerlynx (neratinib)
    A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma (NCT04576117)
    Phase 3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/07/2025
    Initiation :
    02/16/2021
    Primary completion :
    12/30/2026
    Completion :
    12/30/2026
    BRAF • IDH1 • NF1
    |
    BRAF V600E • BRAF V600 • IDH1 mutation • IDH mutation + BRAF V600E
    |
    Koselugo (selumetinib) • vinblastine
    Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer (NCT02101788)
    Phase 2/3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    02/27/2014
    Primary completion :
    04/04/2019
    Completion :
    10/11/2025
    BRAF
    |
    Mekinist (trametinib) • paclitaxel • letrozole • pegylated liposomal doxorubicin • topotecan • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • Soltamox (tamoxifen citrate) • doxorubicin liposomal
    A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors (C4901001) (NCT05538130)
    Phase 1
    Pfizer
    Recruiting
    Last update posted :
    02/06/2025
    Initiation :
    11/30/2022
    Primary completion :
    12/31/2027
    Completion :
    07/03/2029
    BRAF
    |
    BRAF mutation • BRAF V600
    |
    Braftovi (encorafenib) • tinlorafenib (PF-07284890) • PF-07799544 • claturafenib (PF-07799933)
    Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer (NCT02642042)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    07/18/2016
    Primary completion :
    05/15/2019
    Completion :
    03/05/2025
    KRAS • TP53 • STK11
    |
    TP53 mutation • KRAS mutation
    |
    Mekinist (trametinib) • docetaxel • omipalisib (GSK2126458)
    A Study to Compare How Effective is Encorafenib Plus Binimetinib in Real-world and Clinical Trial Settings (NCT05954546)
    Phase N/A
    Pfizer
    Completed
    Last update posted :
    02/05/2025
    Initiation :
    07/21/2023
    Primary completion :
    12/31/2023
    Completion :
    12/31/2023
    BRAF
    |
    BRAF V600E • BRAF V600 • BRAF V600K
    |
    Mektovi (binimetinib) • Braftovi (encorafenib)
    Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) (NCT03213691)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    02/05/2025
    Initiation :
    10/30/2017
    Primary completion :
    06/30/2021
    Completion :
    12/31/2024
    BRAF
    |
    BRAF mutation • BRAF V600
    |
    Koselugo (selumetinib)
    Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients (RAMP 203) (NCT05074810)
    Phase 1/2
    Verastem, Inc.
    Recruiting
    Last update posted :
    02/04/2025
    Initiation :
    04/12/2022
    Primary completion :
    09/01/2025
    Completion :
    04/01/2027
    KRAS
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Lumakras (sotorasib) • avutometinib (VS-6766) • defactinib (VS-6063)
    Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations (BEAVER) (NCT03839342)
    Phase 2
    University Health Network, Toronto
    Active, not recruiting
    Last update posted :
    02/03/2025
    Initiation :
    06/07/2019
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    BRAF • KIAA1549
    |
    BRAF mutation • BRAF V600K • BRAF fusion
    |
    Mektovi (binimetinib) • Braftovi (encorafenib)
    Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC (NCT01933932)
    Phase 3
    AstraZeneca
    Active, not recruiting
    Last update posted :
    01/31/2025
    Initiation :
    09/25/2013
    Primary completion :
    06/07/2016
    Completion :
    12/31/2025
    KRAS
    |
    KRAS mutation
    |
    docetaxel • Koselugo (selumetinib) • Neulasta (pegfilgrastim)
    Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases (NCT05026983)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    01/30/2025
    Initiation :
    12/27/2021
    Primary completion :
    05/01/2025
    Completion :
    05/01/2025
    BRAF
    |
    BRAF mutation • BRAF V600
    |
    Mektovi (binimetinib) • Braftovi (encorafenib)
    Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma (DETERMINE) (NCT06194929)
    Phase 1/2
    University of Utah
    Recruiting
    Last update posted :
    01/30/2025
    Initiation :
    03/07/2024
    Primary completion :
    01/15/2028
    Completion :
    01/15/2030
    NF1 • RAS
    |
    BRAF V600E • BRAF V600K • BRAF wild-type • RAS mutation
    |
    Braftovi (encorafenib) • avutometinib (VS-6766) • defactinib (VS-6063)
    MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (SPRINT) (NCT02407405)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    01/30/2025
    Initiation :
    01/07/2016
    Primary completion :
    01/01/2028
    Completion :
    01/01/2030
    NF1
    |
    NF1 mutation
    |
    Koselugo (selumetinib)
    5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours (NCT06630260)
    Phase 1/2
    Institute of Cancer Research, United Kingdom
    Recruiting
    Last update posted :
    01/22/2025
    Initiation :
    11/15/2024
    Primary completion :
    09/30/2029
    Completion :
    09/30/2030
    BRAF
    |
    temozolomide • avutometinib (VS-6766) • defactinib (VS-6063)
    A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST] (NCT06693284)
    Phase 1
    University of Minnesota
    Recruiting
    Last update posted :
    01/14/2025
    Initiation :
    12/01/2024
    Primary completion :
    01/01/2026
    Completion :
    01/01/2026
    NF1
    |
    Gomekli (mirdametinib) • Zolinza (vorinostat)
    Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN (SPRINKLE) (NCT05309668)
    Phase 1/2
    AstraZeneca
    Active, not recruiting
    Last update posted :
    12/16/2024
    Initiation :
    01/21/2022
    Primary completion :
    04/08/2024
    Completion :
    04/28/2028
    NF1
    |
    Koselugo (selumetinib)
    Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas (NCT05101148)
    Phase 1
    AstraZeneca
    Active, not recruiting
    Last update posted :
    12/10/2024
    Initiation :
    07/21/2021
    Primary completion :
    04/06/2022
    Completion :
    01/12/2026
    NF1
    |
    Koselugo (selumetinib)
    Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas (KOMET) (NCT04924608)
    Phase 3
    AstraZeneca
    Active, not recruiting
    Last update posted :
    12/09/2024
    Initiation :
    11/19/2021
    Primary completion :
    08/05/2024
    Completion :
    03/17/2025
    NF1
    |
    Koselugo (selumetinib)
    Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma (NCT03501368)
    Phase 1
    H. Lee Moffitt Cancer Center and Research Insti...
    Active, not recruiting
    Last update posted :
    12/04/2024
    Initiation :
    06/27/2018
    Primary completion :
    10/28/2022
    Completion :
    01/01/2025
    PD-L1 • BRAF
    |
    BRAF mutation • BRAF V600
    |
    Mekinist (trametinib) • Zykadia (ceritinib)
    A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN) (NCT04590235)
    Phase 1
    AstraZeneca
    Active, not recruiting
    Last update posted :
    11/19/2024
    Initiation :
    12/16/2020
    Primary completion :
    08/16/2022
    Completion :
    08/31/2026
    NF1
    |
    Koselugo (selumetinib)